TrialJournal of the American Academy of Dermatology2018

Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial.

Emma Guttman-Yassky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.